Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

rivogenlecleucel

Allogeneic, T-lymphocytes with potential immune reconstitution activity. Donor T-lymphocytes are transduced with a retroviral vector (BPZ-1001) encoding the inducible suicide gene caspase 9 (iCasp9) and linked to a drug binding domain. Donor T-cell therapy may help control transplant-related infections following allogeneic hematopoietic stem cell transplantation. However, the addition of donor T-cells can lead to graft-versus-host disease (GVHD). In the event that GVHD begins to develop, the chemical homodimerizer AP1903 can be administered, which binds to the drug binding domain and induces caspase 9 expression. This activates apoptosis in the T-cells causing GVHD.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic T lymphocytes BPX-501
Code name:BPX-501
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search